Income statement
USD
Annual
| Metric | 2015 | 2014 | 2013 |
|---|---|---|---|
| Revenue | 495 | 0 | 0 |
| Gross Profit | -20K | 0 | 0 |
| Operating Income | -290K | -55K | -15K |
| EBITDA | -494K | -55K | -15K |
| Net Income | -787K | -55K | -15K |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
That Marketing Solution, Inc. (TSTS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -460.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -460.0%, free cash flow -705.8% with operating margin -58590.9% and ROIC 70.4%. Valuation already assumes a fairly strong business story at price/sales 25.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TSTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSTS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSTS Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSTS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$15.4K
+72.0% YoY
Free Cash Flow
-$13.4K
+62.9% YoY
Revenue Growth
+0.0%
EPS Growth
-460.0%
Gross Margin
-4125.5%
Net Margin
-159019.4%
Income statement
USD
| Metric | 2015 | 2014 | 2013 |
|---|---|---|---|
| Revenue | 495 | 0 | 0 |
| Gross Profit | -20K | 0 | 0 |
| Operating Income | -290K | -55K | -15K |
| EBITDA | -494K | -55K | -15K |
| Net Income | -787K | -55K | -15K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|
| Cash & Equivalents | 894 | 2K | 18K | 3K |
| Total Assets | 121K | 2K | 18K | 3K |
| Total Liabilities | 778K | 25K | 4K | 349 |
| Shareholder Equity | -657K | -22K | 14K | 3K |
| Total Debt | 245K | 0 | 0 | 0 |
| Net Debt | 244K | -2K | -18K | -3K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13K
+62.9% YoY
Capital Expenditures
0
Free Cash Flow
13K
+62.9% YoY
Key ratios
Gross Margin
-4125.5%
Operating Margin
-58590.9%
Net Margin
-159019.4%
ROE
231.6%
Debt / Equity
-0.37x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.